Boundless Bio

Boundless Bio hands Nasdaq listing to Serapha Bio in reverse merger with $230M in financing; CARsgen wins world Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies…

ENDPOINTS · 2026-06-23

Plus news about Definium Therapeutics, uniQure, MoonLake Immunotherapeutics, Versant Ventures, Corxel Pharmaceuticals and US WorldMeds. 🇨🇳 BOLD gives up: Boundless Bio {$BOLD}, which faced clinical setbacks over the years ...

Source: Endpoints News